Xerostomia is a subjective feeling, caused by different reasons, many of the systemic many diseases are complications, some are the result of inevitable development. The side effect of the medicine is also one of the important factors that cause dry mouth. Xerostomia is a condition caused by a lack of saliva in the mouth. The amount of saliva in the mouth depends on the balance between production and consumption. If the amount of saliva produced is less than the amount consumed, there is a negative balance, indicating dry mouth.

Market Analysis and Insights: Global Xerostomia (Dry Mouth Disease) Therapeutics Market
The global Xerostomia (Dry Mouth Disease) Therapeutics market size is projected to reach US$ 673.7 million by 2027, from US$ 554.2 million in 2020, at a CAGR of 2.4% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Xerostomia (Dry Mouth Disease) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Xerostomia (Dry Mouth Disease) Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Xerostomia (Dry Mouth Disease) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Xerostomia (Dry Mouth Disease) Therapeutics market.

Global Xerostomia (Dry Mouth Disease) Therapeutics Scope and Market Size
Xerostomia (Dry Mouth Disease) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Xerostomia (Dry Mouth Disease) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Artificial Saliva
Salivary Stimulants
Saliva Substitutes
Drugs
Salivary Pens
Others

Segment by Application
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Acacia Pharma
Church & Dwight
GlaxoSmithKline
Hikma Pharmaceuticals
Lupin
OraCoat
Parnell Pharmaceuticals
Pendopharm
Pfizer
Sun Pharmaceutical Industries
Synedgen